European Companies Search Engine
EU funding (€8,363,555): ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO) Hor1 Jan 2024 EU Research and Innovation programme "Horizon"
Overview
Text
ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO)
Knee osteoarthritis (OA) is one of the most common causes of pain and disability, affecting over 500 million people worldwide. The tremendous socio-economic burden caused by OA is expected to further increase due to rising life expectancy and obesity. Current therapeutic approaches are limited to pain management or knee arthroplasty, but no disease-modifying or regenerative treatment is available. ENCANTO will address this major unmet clinical need by clinically introducing a combined ATMP for the biological reconstruction of the degenerated joint facet in patellofemoral OA (PFOA). This tissue-engineered cartilage (N-TEC), based on autologous nasal chondrocytes and a collagen membrane, was previously successfully used for focal cartilage lesions. The central part of ENCANTO is an international, blinded, multicenter, prospective randomized controlled phase II trial to clinically assess the efficacy of N-TEC for the treatment of PFOA. Patients’ samples will be analyzed to retrospectively identify PFOA molecular endotypes and associated biomarker signatures with the most successful clinical outcome after N-TEC implantation, to predictively select responders to therapy. To achieve these aims ENCANTO brings together tissue engineers with practice in ATMPs, knee surgery and rehabilitation specialists, research institutes experienced in regulatory affairs, health economics and ATMP development, excellent scientists involved in the assessment of OA endotypes, and patients’ representatives. SMEs from the consortium will develop a road map towards commercial exploitation, including centralized marketing authorization. After demonstrating efficacy for PFOA, N-TEC will be considered for other forms of OA in different joints. ENCANTO will thus introduce the first disease-modifying therapy for cartilage degeneration, enable mobility and social gain for a large patient group and play a pivotal role in strengthening Europe's position in delivering regenerative medicine solutions.
Funded Companies:
| Company name | Funding amount |
| crossklinik AG | ? |
| EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS gGmbH | €347,300 |
| Fondazione Policlinico Universitario Campus BIO Medico | €1,346,800 |
| JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG | €347,300 |
| KLINICKA BOLNICA SVETI DUH | €532,238 |
| Medizinische Universitaet Wien | €445,778 |
| Ortopadisches Spital Speising GmbH | €350,156 |
| Ospedale Galeazzi S.p.A. | €0.00 |
| OULUN YLIOPISTO | €442,848 |
| PROMOVE-BIOTEC GmbH | €440,943 |
| Szpital Specjalistyczny im. Stefana Zeromskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Krakowie | €271,963 |
| Theracell Proigmenes Viotechnologikes Efarmoges Monoprosopi ΑΕ | €248,750 |
| Universita Degli Studi Di Milano | €388,136 |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | €1,880,920 |
| UNIVERSITEIT MAASTRICHT | €506,875 |
| Vastra Gotalandsregionen | €347,300 |
| VIDEOREHA d.o.o. | €466,250 |
Source: https://cordis.europa.eu/project/id/101137315
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: crossklinik AG, Basle, Switzerland.
The visualizations for "crossklinik AG - EU funding (€8,363,555): ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO)"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
